2. Academic Validation
  3. Antibody-mediated inhibition of FXIIa blocks downstream bradykinin generation

Antibody-mediated inhibition of FXIIa blocks downstream bradykinin generation

  • J Allergy Clin Immunol. 2018 Oct;142(4):1355-1358. doi: 10.1016/j.jaci.2018.06.014.
Helen Cao 1,  Mark Biondo 1,  Hadi Lioe 1,  Samantha Busfield 1,  Veronika Rayzman 1,  Bernhard Nieswandt 2,  Konrad Bork 3,  Leonard C Harrison 4,  Priscilla Auyeung 4,  Henriette Farkas 5,  Dorottya Csuka 5,  Matthias Pelzing 1,  Steve Dower 1,  Michael J Wilson 1,  Andrew Nash 1,  Marc W Nolte 6,  Con Panousis 7
Affiliations

Affiliations

  • 1 CSL Limited, BIO21 Institute, Parkville, Victoria, Australia.
  • 2 Department of Experimental Biomedicine, University Hospital Würzburg and Rudolf Virchow Center for Experimental Biomedicine, University of Würzburg, Würzburg, Germany.
  • 3 Department of Dermatology, Johannes Gutenberg University, Mainz, Germany.
  • 4 Walter and Eliza Hall Institute for Medical Research, Parkville, Victoria, Australia; Department of Medical Biology, University of Melbourne, Parkville, Victoria, Australia.
  • 5 Hungarian Angioedema Center, 3rd Department of Internal Medicine, Semmelweis University, Budapest, Hungary.
  • 6 CSL Behring GmbH Emil-Von-Behring-Straße 76, Marburg, Germany.
  • 7 CSL Limited, BIO21 Institute, Parkville, Victoria, Australia. Electronic address: [email protected].
PMID: 29936101 DOI: 10.1016/j.jaci.2018.06.014
Figures
Products